27680876|t|A Variant in the BACH2 Gene Is Associated With Susceptibility to Autoimmune Addison's Disease in Humans
27680876|a|Autoimmune Addison's disease (AAD) is a rare but highly heritable condition. The BACH2 protein plays a crucial role in T lymphocyte maturation, and allelic variation in its gene has been associated with a number of autoimmune conditions. We aimed to determine whether alleles of the rs3757247 single nucleotide polymorphism (SNP) in the BACH2 gene are associated with AAD. This case-control association study was performed in two phases using Taqman chemistry. In the first phase, the rs3757247 SNP was genotyped in 358 UK AAD subjects and 166 local control subjects. Genotype data were also available from 5154 healthy UK controls from the Wellcome Trust (WTCCC2) for comparison. In the second phase, the SNP was genotyped in a validation cohort comprising 317 Norwegian AAD subjects and 365 controls. The frequency of the minor T allele was significantly higher in subjects with AAD from the United Kingdom compared to both the local and WTCCC2 control cohorts (58% vs 45 and 48%, respectively) (local controls, P = 1.1 × 10(-4); odds ratio [OR], 1.68; 95% confidence interval [CI], 1.29-2.18; WTCCC2 controls, P = 1.4 × 10(-6); OR, 1.44; 95% CI, 1.23-1.69). This finding was replicated in the Norwegian validation cohort (P = .0015; OR, 1.41; 95% CI, 1.14-1.75). Subgroup analysis showed that this association is present in subjects with both isolated AAD (OR, 1.53; 95% CI, 1.22-1.92) and autoimmune polyglandular syndrome type 2 (OR, 1.37; 95% CI, 1.12-1.69) in the UK cohort, and with autoimmune polyglandular syndrome type 2 in the Norwegian cohort (OR, 1.58; 95% CI, 1.22-2.06). We have demonstrated, for the first time, that allelic variability at the BACH2 locus is associated with susceptibility to AAD. Given its association with multiple autoimmune conditions, BACH2 can be considered a "universal" autoimmune susceptibility locus.
27680876	2	9	Variant	T028	C0678941
27680876	17	27	BACH2 Gene	T028	C1422394
27680876	47	61	Susceptibility	T201	C0012655
27680876	65	93	Autoimmune Addison's Disease	T047	C0271737
27680876	97	103	Humans	T016	C0086418
27680876	104	132	Autoimmune Addison's disease	T047	C0271737
27680876	134	137	AAD	T047	C0271737
27680876	153	179	highly heritable condition	T047	C0019247
27680876	185	198	BACH2 protein	T116,T123	C1453878
27680876	223	246	T lymphocyte maturation	T043	C2246791
27680876	252	269	allelic variation	T033	C1953357
27680876	277	281	gene	T028	C0017337
27680876	291	306	associated with	T080	C0332281
27680876	319	340	autoimmune conditions	T046	C0004368
27680876	372	379	alleles	T028	C0002085
27680876	387	427	rs3757247 single nucleotide polymorphism	T086	C0752046
27680876	429	432	SNP	T086	C0752046
27680876	441	451	BACH2 gene	T028	C1422394
27680876	456	471	associated with	T080	C0332281
27680876	472	475	AAD	T047	C0271737
27680876	482	512	case-control association study	T062	C0007328
27680876	530	540	two phases	T079	C0205390
27680876	547	563	Taqman chemistry	T059	C1510438
27680876	572	583	first phase	T079	C0205390
27680876	589	602	rs3757247 SNP	T086	C0752046
27680876	607	616	genotyped	T032	C0017431
27680876	627	630	AAD	T047	C0271737
27680876	631	639	subjects	T098	C0080105
27680876	654	661	control	T096	C0009932
27680876	662	670	subjects	T098	C0080105
27680876	672	680	Genotype	T032	C0017431
27680876	681	685	data	T078	C1511726
27680876	716	735	healthy UK controls	T080	C2986479
27680876	745	768	Wellcome Trust (WTCCC2)	T062	C0007328
27680876	792	804	second phase	T079	C0205390
27680876	810	813	SNP	T086	C0752046
27680876	818	827	genotyped	T032	C0017431
27680876	833	850	validation cohort	T098	C0599755
27680876	866	875	Norwegian	T098	C0337812
27680876	876	879	AAD	T047	C0271737
27680876	880	888	subjects	T098	C0080105
27680876	897	905	controls	T096	C0009932
27680876	928	942	minor T allele	T028	C0002085
27680876	971	979	subjects	T098	C0080105
27680876	985	988	AAD	T047	C0271737
27680876	998	1012	United Kingdom	T083	C0041700
27680876	1044	1066	WTCCC2 control cohorts	T098	C0599755
27680876	1102	1116	local controls	T096	C0009932
27680876	1136	1146	odds ratio	T081	C0028873
27680876	1148	1150	OR	T081	C0028873
27680876	1163	1182	confidence interval	T081	C0009667
27680876	1184	1186	CI	T081	C0009667
27680876	1200	1215	WTCCC2 controls	T096	C0009932
27680876	1235	1237	OR	T081	C0028873
27680876	1249	1251	CI	T081	C0009667
27680876	1300	1327	Norwegian validation cohort	T062	C0086027
27680876	1340	1342	OR	T081	C0028873
27680876	1354	1356	CI	T081	C0009667
27680876	1370	1387	Subgroup analysis	T062	C0936012
27680876	1405	1416	association	T033	C0449380
27680876	1431	1439	subjects	T098	C0080105
27680876	1459	1462	AAD	T047	C0271737
27680876	1464	1466	OR	T081	C0028873
27680876	1478	1480	CI	T081	C0009667
27680876	1497	1537	autoimmune polyglandular syndrome type 2	T047	C0085860
27680876	1539	1541	OR	T081	C0028873
27680876	1553	1555	CI	T081	C0009667
27680876	1575	1584	UK cohort	T098	C0599755
27680876	1595	1635	autoimmune polyglandular syndrome type 2	T047	C0085860
27680876	1643	1659	Norwegian cohort	T098	C0599755
27680876	1661	1663	OR	T081	C0028873
27680876	1675	1677	CI	T081	C0009667
27680876	1738	1757	allelic variability	T080	C2986469
27680876	1765	1770	BACH2	T028	C1422394
27680876	1771	1776	locus	T082	C1708726
27680876	1780	1795	associated with	T080	C0332281
27680876	1796	1810	susceptibility	T201	C0012655
27680876	1814	1817	AAD	T047	C0271737
27680876	1829	1845	association with	T080	C0332281
27680876	1846	1876	multiple autoimmune conditions	T046	C0004368
27680876	1878	1883	BACH2	T028	C1422394
27680876	1904	1941	"universal" autoimmune susceptibility	T033	C0243095
27680876	1942	1947	locus	T082	C1708726